Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016. Now available in 21 countries, the pump includes a touch screen.
Lilly plans on commercializing a version of this pump in tandem with a continuous glucose monitor to automate insulin delivery in the U.S. and Europe. The pump would use Lilly’s cartridges containing rapid-acting insulins.
Ypsomed hopes to win FDA permission to use the YpsoPump for automated insulin delivery in 2022. Lilly would have exclusive rights to commercialize the pump in the U.S.
“Our goal is to support people living with diabetes through app-centric insulin management, CGM data and advanced algorithms,” said Simon Michel, Ypsomed CEO, in a statement.
The post Lilly and Ypsomed team up on automated insulin delivery appeared first on Drug Delivery Business.